Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Change in Acquisitions & Divestments (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Change in Acquisitions & Divestments for 3 consecutive years, with $24.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments rose 72.04% to $24.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $110.9 million, a 96.76% increase, with the full-year FY2025 number at $110.9 million, up 96.76% from a year prior.
  • Change in Acquisitions & Divestments was $24.0 million for Q4 2025 at Artiva Biotherapeutics, down from $29.6 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $29.6 million in Q3 2025 to a low of $12.0 million in Q3 2023.
  • A 3-year average of $19.2 million and a median of $15.0 million in 2024 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: rose 3.33% in 2024, then surged 138.9% in 2025.
  • Artiva Biotherapeutics' Change in Acquisitions & Divestments stood at $12.8 million in 2023, then grew by 8.98% to $14.0 million in 2024, then skyrocketed by 72.04% to $24.0 million in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Change in Acquisitions & Divestments are $24.0 million (Q4 2025), $29.6 million (Q3 2025), and $28.2 million (Q2 2025).